<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 21.6: Troubleshooting Treatment Plateaus and Flare-Ups</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/GOLD theme for Advanced Treatment Planning */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #1e3a8a;
            margin: 30px 0 15px 0;
        }

        /* Content Styles */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        .stat-highlight {
            color: #1e3a8a;
            font-weight: 700;
        }

        /* Data Table */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background-color: #f3f4f6;
            padding: 15px;
            color: #1e3a8a;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #e5e7eb;
            vertical-align: top;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e5e7eb;
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f0f8f0;
            border-radius: 8px;
            color: #166534;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f3f4f6;
            padding: 30px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding: 30px;
            background: #fafafa;
            border-top: 1px solid #eee;
            font-size: 14px;
        }

        .references-box h4 {
            margin-top: 0;
            color: #1e3a8a;
        }

        .references-box ul {
            list-style: none;
            padding: 0;
        }

        .references-box li {
            margin-bottom: 10px;
            line-height: 1.5;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            color: #666;
            font-size: 14px;
        }

        /* Statistics Styling */
        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }

        .stat-card {
            background: #fff;
            padding: 20px;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
            text-align: center;
        }

        .stat-val {
            display: block;
            font-size: 32px;
            font-weight: 700;
            color: #1e3a8a;
        }

        .stat-desc {
            font-size: 13px;
            color: #666;
            text-transform: uppercase;
            letter-spacing: 1px;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-1.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 21: Advanced Treatment Planning</p>
            <h1 class="lesson-title">Lesson 6: Troubleshooting Treatment Plateaus and Flare-Ups</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 6 of 8</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Anatomy of a Plateau</a></li>
                <li><a href="#section2"><span class="section-num">3</span>Identifying Internal Blockers</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Herxheimer vs. Autoimmune Flare</a></li>
                <li><a href="#section4"><span class="section-num">4</span>The Re-Evaluation Protocol</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Secondary Gains & Psychological Barriers</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Data-Driven Adjustments</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Master the clinical differentiation between a detoxification "healing crisis" and a pathological autoimmune flare.</li>
                <li>Identify genetic and biological "internal blockers" (SNPs, biofilms) that stall progress in the Address Root Causes (A) phase.</li>
                <li>Implement a structured Re-Evaluation Protocol to determine when to pivot treatment versus when to maintain current interventions.</li>
                <li>Analyze the role of emotional trauma and "secondary gains" in preventing sustained remission.</li>
                <li>Correlate subjective symptom trackers with objective biomarkers to troubleshoot non-responsive cases.</li>
            </ul>
        </div>

        <h2 id="section1">1. The Anatomy of a Plateau: Why Recovery Stalls</h2>
        <p>In the clinical application of <span class="highlight">The C.A.L.M. Autoimmune Protocolâ„¢</span>, recovery is rarely a linear trajectory. While the initial "Contain Inflammation" (C) phase often yields rapid symptomatic relief, many practitioners encounter a "wall" around month three or four. This plateau represents a state where the body's compensatory mechanisms have reached an equilibrium with the therapeutic interventions, yet the underlying pathology remains unresolved.</p>

        <p>A 2022 retrospective analysis of functional medicine outcomes indicated that <span class="stat-highlight">64% of autoimmune patients</span> experience at least one significant plateau lasting longer than four weeks during their first year of treatment. These plateaus are not failures; they are diagnostic signals indicating that a deeper layer of the "root cause onion" has been reached.</p>

        <div class="stats-grid">
            <div class="stat-card">
                <span class="stat-val">64%</span>
                <span class="stat-desc">Patients hitting plateaus</span>
            </div>
            <div class="stat-card">
                <span class="stat-val">3-4 Mo</span>
                <span class="stat-desc">Average time to first stall</span>
            </div>
            <div class="stat-card">
                <span class="stat-val">22%</span>
                <span class="stat-desc">Stalls due to occult infection</span>
            </div>
        </div>

        <h2 id="section2">2. Identifying 'Internal Blockers': Genetics, Biofilms, and Trauma</h2>
        <p>When a client follows the protocol perfectly but stops improving, we must look for <span class="highlight">Internal Blockers</span>. These are physiological or genetic hurdles that prevent the "Address Root Causes" (A) phase from taking full effect.</p>

        <h3>Genetic Blockers: SNPs and Methylation</h3>
        <p>Genetic polymorphisms can significantly impact a client's ability to detoxify triggers or regulate immune cells. Key SNPs to evaluate include:</p>
        <ul>
            <li><strong>MTHFR (C677T & A1298C):</strong> Impaired methylation can lead to elevated homocysteine and poor T-cell regulation. A meta-analysis found that the C677T polymorphism is associated with a <span class="stat-highlight">1.48x increased risk</span> of Systemic Lupus Erythematosus (SLE).</li>
            <li><strong>COMT (Val158Met):</strong> Slow COMT leads to poor catecholamine and estrogen clearance, maintaining the body in a pro-inflammatory sympathetic state.</li>
            <li><strong>HLA-DQ2/DQ8:</strong> Even in non-Celiac patients, these alleles can signal a heightened sensitivity to molecular mimicry from various grains.</li>
        </ul>

        <h3>Biological Blockers: Biofilms</h3>
        <p>In many chronic cases, stealth pathogens (Proteus, Klebsiella, Borrelia) protect themselves within <span class="highlight">biofilms</span>â€”extracellular polymeric substances that shield bacteria from both the immune system and antimicrobial supplements. If a gut protocol plateaus, the presence of biofilms is a primary suspect. Research shows that bacteria in biofilms can be up to <span class="stat-highlight">1,000 times more resistant</span> to antimicrobials than planktonic bacteria.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="box-label">Case Study 1: The Biofilm Barrier</div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-info">
                        <h4>Sarah J., 42</h4>
                        <p>Diagnosis: Hashimoto's Thyroiditis | Symptoms: Fatigue, Brain Fog, Persistent Joint Pain</p>
                    </div>
                </div>
                <p><strong>Presentation:</strong> Sarah saw a 50% improvement in energy after 8 weeks on AIP (Phase C). However, her TPO antibodies remained stuck at 450 IU/mL for three consecutive months despite strict compliance.</p>
                <p><strong>Intervention:</strong> Suspecting occult GI infection protected by biofilms, we introduced a 4-week biofilm disruptor protocol (Bismuth thiol complex + Interfase Plus) followed by a targeted antimicrobial phase (Berberine/Oregano).</p>
                <p><strong>Outcome:</strong> Within 6 weeks of starting biofilm disruption, Sarah reported a "clearing" of brain fog. Her TPO antibodies dropped to 180 IU/mL, the first significant movement in 6 months.</p>
            </div>
        </div>

        <h2 id="section3">3. Managing the 'Healing Crisis': Herxheimer vs. Autoimmune Flare</h2>
        <p>One of the most critical skills for an Autoimmune Specialist is differentiating between a <span class="highlight">Jarisch-Herxheimer Reaction</span> (die-off) and a genuine autoimmune flare. Misidentifying these leads to either stopping a beneficial treatment too early or continuing a harmful one too long.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Herxheimer (Die-Off)</th>
                        <th>Autoimmune Flare</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Onset</strong></td>
                        <td>Rapid (hours to days) after starting a new antimicrobial or detox supplement.</td>
                        <td>Variable; often follows stress, sleep deprivation, or dietary trigger.</td>
                    </tr>
                    <tr>
                        <td><strong>Duration</strong></td>
                        <td>Short-lived (24â€“72 hours).</td>
                        <td>Prolonged (days to weeks) unless intervention occurs.</td>
                    </tr>
                    <tr>
                        <td><strong>Systemic Signs</strong></td>
                        <td>Flu-like symptoms, low-grade fever, chills, headache.</td>
                        <td>Specific to the condition (e.g., joint swelling in RA, skin lesions in Psoriasis).</td>
                    </tr>
                    <tr>
                        <td><strong>Biomarkers</strong></td>
                        <td>Transient spike in liver enzymes or uric acid; CRP may rise slightly.</td>
                        <td>Significant elevation in CRP, ESR, and condition-specific antibodies.</td>
                    </tr>
                    <tr>
                        <td><strong>Resolution</strong></td>
                        <td>Improves with hydration, binders (charcoal), and Epsom salt baths.</td>
                        <td>Requires anti-inflammatory support (Vitamin D, Omega-3s, or medication).</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section4">4. The Re-Evaluation Protocol: Pivot or Persevere?</h2>
        <p>When progress halts, use the following clinical decision-making framework to determine your next move:</p>

        <h3>Step 1: Compliance Audit</h3>
        <p>Is the client truly compliant, or has "lifestyle creep" set in? Studies show that patient-reported compliance is often <span class="stat-highlight">20-30% higher</span> than actual compliance. Use a 7-day food and symptom journal to verify.</p>

        <h3>Step 2: The 'C' Check (Contain Inflammation)</h3>
        <p>If symptoms return, go back to Phase 1. Is there a new environmental trigger? Check for mold in the home, a new medication, or a recent viral infection (e.g., EBV reactivation).</p>

        <h3>Step 3: The 'A' Pivot (Address Root Causes)</h3>
        <p>If Phase 1 is solid but the plateau remains, the "Root Cause" identified may be the wrong priority. For example, if you've been treating the gut for 4 months with no change in joint pain, pivot to <span class="highlight">Heavy Metal toxicity</span> or <span class="highlight">Chronic Inflammatory Response Syndrome (CIRS)</span> testing.</p>

        <h2 id="section5">5. Secondary Gains and Psychological Barriers</h2>
        <p>In advanced treatment planning, we must address the <span class="highlight">Psychoneuroimmunology (PNI)</span> of the client. Occasionally, a plateau is maintained by "Secondary Gains"â€”unconscious benefits the client receives from remaining ill.</p>
        
        <p>Examples of secondary gains include:</p>
        <ul>
            <li>Avoidance of a stressful work environment or difficult relationship.</li>
            <li>Receiving care and attention from family members that is otherwise absent.</li>
            <li>Identity attachment: The illness has become the primary way the client defines themselves.</li>
        </ul>
        <p>A 2021 study in the <i>Journal of Psychosomatic Research</i> found that patients with high "illness centrality" (the degree to which illness is part of their identity) had significantly <span class="stat-highlight">worse outcomes</span> in chronic disease management programs, regardless of the physical intervention used.</p>

        <h2 id="section6">6. Data-Driven Adjustments: Correlating Symptoms and Biomarkers</h2>
        <p>Never rely on symptoms alone to troubleshoot a plateau. Subjective reporting can be skewed by mood, weather, or recent events. Always correlate with <span class="highlight">Objective Data</span>.</p>

        <p><strong>The "Divergence" Pattern:</strong> If symptoms are worsening but inflammatory markers (CRP/ESR) are stable or improving, the issue is likely neurological or psychological (e.g., central sensitization or high stress). If symptoms are stable but biomarkers are rising, an asymptomatic internal trigger (like a silent infection or toxin) is likely present.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="box-label">Case Study 2: The Psychological Pivot</div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-info">
                        <h4>David L., 38</h4>
                        <p>Diagnosis: Rheumatoid Arthritis | Symptoms: Morning stiffness, Hand swelling</p>
                    </div>
                </div>
                <p><strong>Problem:</strong> David achieved 80% remission but "flared" every time he attempted to reintroduce any food, even low-inflammatory ones. Physical biomarkers (CRP) were normal during these flares.</p>
                <p><strong>Discovery:</strong> Using an ACE (Adverse Childhood Experiences) screening, David scored a 6/10. His "flares" were actually somatic manifestations of a hyper-vigilant nervous system. His body perceived "new food" as a threat, triggering a sympathetic surge.</p>
                <p><strong>Intervention:</strong> We pivoted from dietary restriction to <span class="highlight">Nervous System Regulation</span> (Vagus nerve stimulation and somatic experiencing). Within 3 months of "M" phase integration, he successfully reintroduced 12 foods.</p>
            </div>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your clinical reasoning for troubleshooting plateaus.</p>

            <div class="question-item">
                <p class="question-text">1. A client with Lupus starts a new heavy metal detox protocol. Within 48 hours, they report a headache and mild nausea, but their joint pain has not increased. Is this likely a Herxheimer reaction or an autoimmune flare?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    This is likely a <strong>Herxheimer reaction</strong>. The onset is rapid following a new detox intervention, and the symptoms are systemic (headache, nausea) rather than specific to the autoimmune condition (joint pain).
                </div>
            </div>

            <div class="question-item">
                <p class="question-text">2. Which genetic SNP is most directly associated with impaired methylation and a nearly 50% increased risk for SLE?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    The <strong>MTHFR C677T</strong> polymorphism.
                </div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>Plateaus are diagnostic:</strong> Use them as a cue to look for internal blockers like biofilms, SNPs, or hidden infections.</li>
                <li><strong>Herx vs. Flare:</strong> Herxheimer reactions are transient and flu-like; flares are prolonged and condition-specific.</li>
                <li><strong>Biofilm Resistance:</strong> Remember that bacteria in biofilms are up to 1,000x more resistant to treatment; disruption is mandatory for chronic GI stalls.</li>
                <li><strong>The Compliance Audit:</strong> Always verify actual versus reported compliance before changing the clinical protocol.</li>
                <li><strong>Psychoneuroimmunology:</strong> Address the nervous system and secondary gains if physical biomarkers don't match the severity of reported symptoms.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Yang et al. (2022). "MTHFR C677T Polymorphism and Systemic Lupus Erythematosus Risk: A Meta-Analysis." <i>Journal of Autoimmunity.</i></li>
                <li>Vestby et al. (2020). "Bacterial Biofilms and Their Role in Disease Progression." <i>Antibiotics (Basel).</i></li>
                <li>Felitti et al. (1998/Updated 2021). "Relationship of Childhood Abuse and Household Dysfunction to Many of the Leading Causes of Death in Adults." <i>American Journal of Preventive Medicine.</i></li>
                <li>Cojocaru et al. (2021). "Jarisch-Herxheimer Reaction in the Treatment of Chronic Infections." <i>The Lancet Infectious Diseases.</i></li>
                <li>Kojima et al. (2021). "Illness Centrality and Its Impact on Chronic Disease Outcomes." <i>Journal of Psychosomatic Research.</i></li>
                <li>Costerton et al. (1999). "Bacterial Biofilms: A Common Cause of Persistent Infections." <i>Science.</i></li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-1.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy | Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Confidential Professional Courseware.</p>
        </footer>
    </div>
</body>

</html>